References
- Ames, B. N., Cathcart, R., Schwiers, E., Hochstein P. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci.,78 (11), 6858–6862.10.1073/pnas.78.11.68583491516947260
- Bardin, T., Keenan, R.T., Khanna, P. P., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard, C., Baumgartner, S., So, A. (2017). Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis., 76 (5), 811–820.10.1136/annrheumdis-2016-209213553033627821644
- Becker, M. A., Schumacher, R. H., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl. J. Med.,353 (23), 2450–2461.10.1056/NEJMoa05037316339094
- Becker, B. D., Coremans, C., Chaumont, M., Delporte, C., Antwerpen, P. V., Franck, T., Rousseau, A., Boudjeltia, K. Z., Cullu, P., Borne, P. V. D. (2019). Severe hypouricemia impairs endothelium-dependent vasodilatation and reduces blood pressure in healthy young men: A randomized, placebo-controlled, and crossover study. J. Amer. Heart Assoc.,8 (23), e013130.10.1161/JAHA.119.013130691296731752638
- Bellomo, G., Selvi, A. (2018). Uric acid: The lower the better? Contrib. Nephrol., 192, 69–76.
- Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi A., Hiyane M. I., Davanso M. R., Latz E., Franklin B. S., Kowaltowksi A., Camara, N. O. S. (2017). Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep.,7 (1), 39884.
- Bowman, G. L., Shannon, J., Frei, B., Kaye, J. A., Quinn, J. F. (2010). Uric acid as a CNS antioxidant. J. Alzheimers Dis.,19 (4), 1331–1336.10.3233/JAD-2010-1330285918520061611
- Chen, X., Guo, X., Huang, R., Chen, Y., Zheng, Z., Shang, H. (2014). Serum uric acid levels in patients with Alzheimer’s Disease: A meta-analysis. PLOS ONE,9 (4), e94084.10.1371/journal.pone.0094084397975624714617
- Cho, S. K., Chang, Y., Kim, I., Ryu, S. (2018). U-Shaped association between serum uric acid level and risk of mortality. Arthritis Rheumatol.,70 (7), 1122–1132.10.1002/art.4047229694719
- Dalbeth, N., Jones, G., Terkeltaub, R., Khanna, D., Kopicko, J., Bhakta, N., Adler, S., Fung, M., Storgard, C., Baumgartner, S., Perez-Ruiz, F. (2017). Lesinurad, a selective uric acid reabsorption inhibitor, in combination with Febuxostat in patients with tophaceous gout: Findings of a Phase III clinical trial. Arthritis Rheumatol.,69 (9), 1903–1913.10.1002/art.40159560120028597604
- Esparza Martin, N., Garcia Nieto, V. (2011). Hypouricemia and tubular transport of uric acid. Revista Nefrologia, 31, 44–50.
- Fang, P., Li, X., Luo, J.J., Wang, H., Yang, X. (2013). A double-edged sword: Uric acid and neurological disorders. Brain Disord. Ther.,2 (2), 109.
- Fujinaga, S., Ito, A., Nakagawa, M., Watanabe, T., Ohtomo, Y., Shimizu, T. (2013). Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur. J. Pediatrics, 172 (11), 1557–1560.10.1007/s00431-013-1986-723525542
- Graf, S. W., Whittle, S. L., Wechalekar, M. D., Moi, J. H. Y., Barrett, C., Hill, C. L., Littlejohn, G., Lynch, N., Major, G., Taylor, A. L., Buchbinder, R., Zochling, J. (2015). Australian and New Zealand recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion in the 3e Initiative. Int. J. Rheum. Dis.,18 (3), 341–351.10.1111/1756-185X.1255725884565
- Hui, M., Carr, A., Cameron, S., Davenport, D., Doherty, M., Forrester, H.., Jenkins, W., Jordan, K. M., Mallen, C. D., McDonald, T. M., Nuki, G., Pywell, A., Zhang, W., Roddy, E. (2017). The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology, 56 (7), e1–e20.
- Kanbay, M., Segal, M., Afsar, B., Kang, D.-H., Rodriguez-Iturbe, B., Johnson, R. J. (2013). The role of uric acid in the pathogenesis of human cardiovascular disease. Heart, 99 (11), 759–766.10.1136/heartjnl-2012-302535
- Kiltz, U., Alten, R., Fleck, M., Krüger, K., Manger, B., Müller-Ladner, U., Nuesslein, H., Reuss-Borst, M., Schwarting, A., Schulze-Koops, H., Tausche, A., Braun, J., (2017). Evidenzbasierte Empfehlung zur Diagnostik und Therapie der Gichtarthritis im fachärztlichen Sektor. Zeitschrift für Rheumatologie, 76 (2), 118–124 (in German).10.1007/s00393-016-0249-1
- Kocahan, S., Doğan, Z. (2017). Mechanisms of Alzheimer’s Disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, Tau protein and other risk factors. Clin. Psycho-pharmacol. Neurosci.,15 (1), 1–8.10.9758/cpn.2017.15.1.1
- Kuwabara, M. (2016). Hyperuricemia, cardiovascular disease, and hypertension. Pulse, 3 (3–4), 242–252.10.1159/000443769
- Longo, F. M., Massa, S. M. (2004). Neuroprotective strategies in Alzheimer’s disease. NeuroRx, 1 (1), 117–127.10.1602/neurorx.1.1.117
- Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., Mollace, V. (2016). Regulation of uric acid metabolism and excretion. Int. J. Cardiol.,213, 8–14.10.1016/j.ijcard.2015.08.109
- Mattson, M. P. (2003). Excitotoxic and excitoprotective mechanisms: Abundant targets for the prevention and treatment of neurodegenerative disorders. NeuroMolecular Med., 3, 65–94.10.1385/NMM:3:2:65
- Mount, D. B., Sterns, R. H., Forman, J. P. (2020). Hypouricemia: Causes and clinical significance. UptoDate. https://www.uptodate.com/contents/hypouricemia-causes-and-clinical-significance (accessed 15 March 2021).
- Nakayama, A., Matsuo, H., Ohtahara, A., Ogino, K., Hakoda, M., Hamada, T., Hosoyamada, M., Yamaguchi, S., Hisatome, I., Shinomiya, N. (2019). Clinical practice guideline for renal hypouricemia (1st edition). Human Cell, 32 (2), 83–87.10.1007/s13577-019-00239-3643729230783949
- Olivares, D., Deshpande, V. K., Shi, Y., Lahiri, D. K., Greig, N. H., Rogers, J. T., Huang, X. (2012). N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s Disease, vascular dementia and Parkinson’s Disease. Curr. Alzheimer Res.,9 (6), 746–758.10.2174/156720512801322564500234921875407
- Paganoni, S., Schwarzschild, M. A. (2016). Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics, 14 (1), 148–153.
- Pello, S., Boland, T., Dechant, V., Patel, S., Liang, T., Mandel, S. (2009). Uric acid’s relationship with stroke and Parkinson’s Disease: A review. Pract. Neurol.https://practicalneurology.com/articles/2009-july-aug/PN0809_07-php (accessed 15 March 2021).
- Perez-Gomez, M. V., Bartsch, L.-A., Castillo-Rodriguez, E., Fernandez-Prado, R., Kanbay, M., Ortiz, A. (2019). Potential dangers of serum urate-lowering therapy. Amer. J. Med.,132 (4), 457–467.10.1016/j.amjmed.2018.12.01030611833
- Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis., 76 (1), 29–42.10.1136/annrheumdis-2016-20970727457514
- Saag, K. G., Fitz-Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard C., Baumgartner S., Becker, M. A. (2017). Lesinurad combined with allopurinol: A randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based Study). Arthritis Rheumatol.,69 (1), 203–212.10.1002/art.3984027564409
- Sautner, J., Gruber, J., Herold, M., Zwerina, J., Leeb, B. F. (2013). Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013. Wiener Klinische Wochenschrift,126 (3–4), 79–89 (in German).
- Sautin, Y. Y., Johnson, R. J. (2008). Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucl. Acids,27 (6), 608–619.10.1080/15257770802138558289591518600514
- Settle, T. (2014). The role of uric acid as an antioxidant in selected neurodegenerative disease pathogenesis: A short review. Brain Disord. Ther.,03 (03). https://www.researchgate.net/publication/269980495_The_Role_of_Uric_Acid_as_an_Antioxidant_in_Selected_Neurodegenerative_Disease_Pathogenesis_A_Short_Review (accessed 15 March 2021).
- Singh, J. (2019). Gout and neurological disease. Is there a link? Annual American College of Rheumatology Convergence, 11 November 2020.Atlanta, GA, USA.
- Squadrito, G. L., Cueto, R., Splenser, A. E., Valavanidis, A., Zhang, H., Uppu, R. M., Pryor, W. A. (2000). Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys., 376, 333–337.10.1006/abbi.2000.172110775420
- Son, C.-N., Kim, J.-M., Kim, S.-H., Cho, S.-K., Choi, C.-B., Sung, Y.-K., Kim T.-H., Bae S.-C., Yoo D.-H., Jun, J.-B. (2016). Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean J. Intern. Med.,31 (5), 971–976.10.3904/kjim.2015.125501628226956409
- Sundy, J. S., Baraf, H. S. B., Yood, R. A., Lawrwnce Edwards, N., Gutierrez-Urena, S. R., Treadwell, E. L., Vasquez-Mellado, J., White, W. B., Lipsky, P., Horowitz, Z., et al. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA,306 (7), 711–720.
- Tana, C., Ticinesi, A., Prati, B., Nouvenne, A., Meschi, T. (2018). Uric acid and cognitive function in older individuals. Nutrients, 10 (8), 975.10.3390/nu10080975611579430060474
- Tausche, A.-K., Alten, R., Dalbeth, N., Kopicko, J., Fung, M., Adler, S., Bhakta N., Baumgartner S., Saag, K. (2017). Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology, 56 (12), 2170–2178.10.1093/rheumatology/kex35029029210
- Weinstein, J. R, Anderson, S. (2010). The aging kidney: Physiological changes. Advances Chron. Kidney Dis.,17 (4), 302–307.10.1053/j.ackd.2010.05.002290162220610357
- White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Gunawardhana, L., CARES Investigators (2018). Cardiovas-cular safety of febuxostat or allopurinol in patients with gout. New Engl. J. Med.,378 (13), 1200–1210.10.1056/NEJMoa171089529527974
- Yu, K.-H., Chen, D.-Y., Chen, J.-H., Chen, S.-Y., Chen, S.-M., Cheng, T.-T., Hsieh, S.-C., Hsieh, T.-Y., Hsu, P.-F., Kuo, C.-F., et al. (2018). Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int. J. Rheum. Dis.,21 (4), 772–787.10.1111/1756-185X.1326629363262
- Zhang, W., Iso, H., Murakami, Y., Miura, K., Nagai, M., Sugiyama, D., Ueshima H., Okamura, T. (2016). Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. J. Atherosclerosis Thrombosis, 23 (6), 692–703.10.5551/jat.31591739928026887218